A PHASE 1 STUDY TO ASSESS SAFETY AND TOLERABILITY OF REGN5837 AN ANTI-CD22 X ANTI-CD28 COSTIMULATORY BISPECIFIC MONOCLONAL ANTIBODY IN COMBINATION WITH ODRONEXTAMAB AN ANTI-CD20 X ANTI-CD3 BISPECIFIC MONOCLONAL ANTIBODY IN PATIENTS WITH AGGRESSIVE
Brief description of study
The goal of this study is to investigate how safe and effective the combining of two different antibodies, REGN5837 and odronextamab (REGN1979), is in patients with aggressive B-cell non Hodgkin lymphoma (B-NHL) that has relapsed or is resistant to treatment. This study is divided into two phases: dose escalation and dose expansion. Dose escalation means increasing the amount of medicine given to patients in a gradual and controlled manner. Dose expansion, on the other hand, involves enrolling more patients in a study at the selected dose level. Previous research has shown that odronextamab has had positive effects in patients with aggressive B-NHL in a separate study. This study aims to evaluate the combined effects of REGN5837 and odronextamab in patients with aggressive B-NHL, excluding mantle cell lymphoma (MCL).
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
